5HB Stock Overview Shanghai Haohai Biological Technology Co., Ltd. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Shanghai Haohai Biological Technology Co., Ltd. Competitors Price History & Performance
Summary of share price highs, lows and changes for Shanghai Haohai Biological Technology Historical stock prices Current Share Price HK$3.12 52 Week High HK$4.70 52 Week Low HK$2.60 Beta 0.77 1 Month Change -4.29% 3 Month Change -20.81% 1 Year Change 8.66% 3 Year Change -23.37% 5 Year Change -7.46% Change since IPO -29.72%
Recent News & Updates
Shanghai Haohai Biological Technology Co., Ltd. to Report Fiscal Year 2024 Results on Mar 22, 2025 Dec 27
Third quarter 2024 earnings released: EPS: CN¥2.19 (vs CN¥0.36 in 3Q 2023) Oct 28
Investor sentiment improves as stock rises 21% Sep 30
Shanghai Haohai Biological Technology Co., Ltd. to Report Q3, 2024 Results on Oct 26, 2024 Sep 30
Shanghai Haohai Biological Technology Co., Ltd. Approves Interim Dividend for the Six Months Ended 30 June 2024 Sep 13
Upcoming dividend of CN¥0.40 per share Sep 13 See more updates
Shanghai Haohai Biological Technology Co., Ltd. to Report Fiscal Year 2024 Results on Mar 22, 2025 Dec 27
Third quarter 2024 earnings released: EPS: CN¥2.19 (vs CN¥0.36 in 3Q 2023) Oct 28
Investor sentiment improves as stock rises 21% Sep 30
Shanghai Haohai Biological Technology Co., Ltd. to Report Q3, 2024 Results on Oct 26, 2024 Sep 30
Shanghai Haohai Biological Technology Co., Ltd. Approves Interim Dividend for the Six Months Ended 30 June 2024 Sep 13
Upcoming dividend of CN¥0.40 per share Sep 13 Shanghai Haohai Biological Technology Co., Ltd. (SEHK:6826) announces an Equity Buyback for 2,229,405 shares, representing 0.95% for CNY 200 million.
Shanghai Haohai Biological Technology Co., Ltd. to Report First Half, 2024 Results on Aug 17, 2024 Jun 28
New major risk - Revenue and earnings growth Jun 20
Shanghai Haohai Biological Technology Co., Ltd. Announces to Distribute A Final Dividend for the Year Ended 31 December 2023 May 30
Upcoming dividend of CN¥1.00 per share May 30
First quarter 2024 earnings released: EPS: CN¥0.58 (vs CN¥0.47 in 1Q 2023) Apr 30
Shanghai Haohai Biological Technology Co., Ltd., Annual General Meeting, May 29, 2024 Apr 28
New major risk - Revenue and earnings growth Apr 18
Full year 2023 earnings released: EPS: CN¥2.44 (vs CN¥1.04 in FY 2022) Apr 17
Shanghai Haohai Biological Technology Co., Ltd. to Report Q1, 2024 Results on Apr 30, 2024 Mar 30
Full year 2023 earnings released Feb 25
New major risk - Revenue and earnings growth Feb 24
Now 21% overvalued Feb 08
Investor sentiment deteriorates as stock falls 16% Feb 01
Shanghai Haohai Biological Technology Co., Ltd. Provides Preliminary Unaudited Consolidated Group Earnings Guidance for the Year Ended 31 December 2023 Jan 30
Shanghai Haohai Biological Technology Co., Ltd. Announces Resignation of Guo Yongqing as Independent Non-Executive Director, Chairman of Audit Committee, Member of Remuneration and Appraisal Committee and Member of Nomination Committee Dec 01
Third quarter 2023 earnings released: EPS: CN¥0.71 (vs CN¥0.32 in 3Q 2022) Oct 26
Investor sentiment deteriorates as stock falls 15% Oct 20
Shanghai Haohai Biological Technology Co., Ltd. Provides Unaudited Consolidated Financial Guidance for the Nine Months Ended 30 September 2023 Sep 26
Investor sentiment improves as stock rises 17% Aug 25
Shanghai Haohai Biological Technology Co., Ltd. (SEHK:6826) announces an Equity Buyback. Aug 19
Second quarter 2023 earnings released: EPS: CN¥0.73 (vs CN¥0.059 in 2Q 2022) Aug 18 Shanghai Haohai Biological Technology Co., Ltd. (SEHK:6826) entered into the equity transfer agreement to acquire 36.3636% stake in OHMK Medical Technology Co. Ltd. from Tianjin Huacan Enterprise Management Consulting Partnership, Shanghai Ermei Enterprise Management Consulting Partnership, Yuan Yibing, Lian Songyong and Chen Guangfei for approximately CNY 150 million. Aug 03
Shanghai Haohai Biological Technology Co., Ltd. Provides Consolidated Earnings Guidance for the Six Months Ended 30 June 2023 Jul 23
Shanghai Haohai Biological Technology Co., Ltd. to Report First Half, 2023 Results on Aug 18, 2023 Jun 28
Upcoming dividend of HK$0.44 per share at 1.4% yield Jun 27
Shanghai Haohai Biological Technology Co., Ltd. Approves Final Dividend for the Year Ended 31 December 2022, Payable on August 11, 2023 Jun 13 Shanghai Haohai Biological Technology Co., Ltd., Annual General Meeting, Jun 12, 2023
First quarter 2023 earnings released: EPS: CN¥0.47 (vs CN¥0.35 in 1Q 2022) Apr 30
Full year 2022 earnings released: EPS: CN¥1.04 (vs CN¥2.00 in FY 2021) Mar 01
Investor sentiment improved over the past week Dec 29
Less than half of directors are independent Nov 16
Shanghai Haohai Biological Technology Co., Ltd. to Report Q3, 2022 Results on Oct 28, 2022 Oct 19
Investor sentiment deteriorated over the past week Oct 04
Second quarter 2022 earnings released: EPS: CN¥0.059 (vs CN¥0.76 in 2Q 2021) Aug 28
Shanghai Haohai Biological Technology Co., Ltd. to Report First Half, 2022 Results on Aug 26, 2022 Aug 17
Shanghai Haohai Biological Technology Co., Ltd. Provides Financial Guidance for the Six Months Ended 30 June 2022 Jul 30
Upcoming dividend of HK$0.82 per share Jul 22 Shanghai Haohai Biological Technology Co., Ltd. Approves Final Dividend for the Year Ended 31 December 2021
Investor sentiment improved over the past week Jun 21
Shanghai Haohai Biological Technology Co., Ltd. Announces Retirement of Li Yingqi as Independent Non-Executive Director Jun 09 Shanghai Haohai Biological Technology Co., Ltd., Annual General Meeting, Jun 29, 2022
Full year 2021 earnings released: EPS: CN¥2.00 (vs CN¥1.30 in FY 2020) Apr 30
Less than half of directors are independent Apr 27
Shanghai Haohai Biological Technology Co., Ltd. to Report Q1, 2022 Results on Apr 29, 2022 Apr 20
Shanghai Haohai Biological Technology Co., Ltd. Proposes Ordinary Final Dividend for the Year Ended December 31, 2021 Mar 30
Investor sentiment improved over the past week Mar 23
Full year 2021 earnings: Revenues miss analyst expectations Mar 02
Shanghai Haohai Biological Technology Co., Ltd. Provides Group Earnings Guidance for the Year Ended 31 December 2021 Jan 30
Third quarter 2021 earnings released: EPS CN¥0.45 (vs CN¥0.50 in 3Q 2020) Oct 31
Second quarter 2021 earnings released: EPS CN¥0.76 (vs CN¥0.29 in 2Q 2020) Aug 27
Investor sentiment deteriorated over the past week Jul 26
Upcoming dividend of HK$0.61 per share Jul 08
Investor sentiment improved over the past week Jun 29
Shanghai Haohai Biological Technology Co., Ltd. Provides Unaudited Consolidated Earnings Guidance for the Six Months Ending June 30, 2021 Jun 26
Investor sentiment improved over the past week May 28
Shanghai Haohai Biological Technology Co., Ltd. (SEHK:6826) entered into the share purchase agreement to acquire an additional 9% stake in Contamac Holdings Limited from John Alexander McGregor for £5.9 million. May 22
Investor sentiment improved over the past week May 04
First quarter 2021 earnings released: EPS CN¥0.55 (vs CN¥0.14 loss in 1Q 2020) Apr 25
Shanghai Haohai Biological Technology Co., Ltd. Provides Preliminary Unaudited Consolidated Earnings Guidance for the Three Months Ending March 31, 2021 Mar 28
Full year 2020 earnings released: EPS CN¥1.30 (vs CN¥2.28 in FY 2019) Mar 28
Shanghai Haohai Biological Technology Co., Ltd. to Report Fiscal Year 2020 Results on Mar 27, 2021 Mar 05
Investor sentiment deteriorated over the past week Mar 02 Shanghai Haohai Biological Technology Co., Ltd. (SEHK:6826) signed the share transfer agreement to acquire 38.23% in Ouhua Meike (Tianjin) Medical Technology Co., Ltd. from Welly And Bloom Ltd and Refined Beauty By Beth Ltd for approximately CNY 140 million.
New 90-day high: €7.20 Feb 18
New 90-day high: €5.75 Jan 14
Investor sentiment improved over the past week Jan 09
New 90-day low: €4.74 Nov 26
Third quarter earnings released Oct 29
New 90-day low: €4.86 Oct 21
New 90-day low: €5.35 Oct 06
Earnings released Aug 28
New 90-day high - €7.10 Aug 04
Shanghai Haohai Biological Technology Co., Ltd. to Report First Half, 2020 Results on Aug 28, 2020 Jul 17 Shareholder Returns 5HB DE Biotechs DE Market 7D 5.4% -2.1% 3.0% 1Y 8.7% -3.8% 12.8%
See full shareholder returns
Return vs Market: 5HB underperformed the German Market which returned 12.8% over the past year.
Price Volatility Is 5HB's price volatile compared to industry and market? 5HB volatility 5HB Average Weekly Movement 5.9% Biotechs Industry Average Movement 6.2% Market Average Movement 4.8% 10% most volatile stocks in DE Market 11.5% 10% least volatile stocks in DE Market 2.4%
Stable Share Price: 5HB has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: 5HB's weekly volatility (6%) has been stable over the past year.
About the Company Shanghai Haohai Biological Technology Co., Ltd. engages in the research, development, manufacture, and sale of biomedical materials in China, Europe, the United States, and internationally. The company offers ophthalmology products consisting intraocular lens, medical sodium hyaluronate gel, and lubricant eye drop.
Show more Shanghai Haohai Biological Technology Co., Ltd. Fundamentals Summary How do Shanghai Haohai Biological Technology's earnings and revenue compare to its market cap? 5HB fundamental statistics Market cap €1.60b Earnings (TTM ) €57.15m Revenue (TTM ) €364.91m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) 5HB income statement (TTM ) Revenue CN¥2.75b Cost of Revenue CN¥848.86m Gross Profit CN¥1.90b Other Expenses CN¥1.47b Earnings CN¥430.21m
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Mar 22, 2025
Earnings per share (EPS) 1.87 Gross Margin 69.10% Net Profit Margin 15.66% Debt/Equity Ratio 7.0%
How did 5HB perform over the long term?
See historical performance and comparison Dividends
3.3% Current Dividend Yield
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2025/01/20 11:57 End of Day Share Price 2025/01/17 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Shanghai Haohai Biological Technology Co., Ltd. is covered by 16 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Jingwei Qi China Merchants Securities Co. Ltd. Xiaofang Xu Citic Securities Co., Ltd. Eva Zhao Citigroup Inc
Show 13 more analysts 
